^
    6d
    Molecular Classification and Clinical Outcomes in Endometrial Cancer: Real-World Evidence from a Tertiary Care Center. (PubMed, Cancers (Basel))
    MMR and p53 IHC serve as practical frontline tools, while POLE sequencing should be prioritized for intermediate- and high-risk endometrioid tumors. Expanded molecular testing in Asian populations is essential to refine risk stratification and optimize individualized management.
    Clinical data • Journal • HEOR • Real-world evidence
    |
    POLE (DNA Polymerase Epsilon) • POLD1 (DNA Polymerase Delta 1)
    |
    TP53 mutation • MSI-H/dMMR • POLE mutation • POLD1 mutation
    |
    Idylla™ POLE-POLD1 Mutation Assay
    10ms
    Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay (Biocartis Press Release)
    "Biocartis NV...to announce the launch of the brand-new Idylla™ POLE-POLD1 Mutation Assay (RUO1), a fully automated, real-time polymerase chain reaction (PCR) Assay designed for the detection of the hypermutated phenotype associated with mutations in POLE and POLD1"
    Launch • Clinical data
    |
    Idylla™ POLE-POLD1 Mutation Assay